Education
About Us
Working with TipRanks
Follow Us
Poniard (PARD)
:PARD
PARD Stock Chart & Stats
$0.31
>-$0.01(-99.00%)
At close: 4:00 PM EST
$0.31
>-$0.01(-99.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume125.00
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PARD FAQ
What was Poniard’s price range in the past 12 months?
Currently, no data Available
What is Poniard’s market cap?
Currently, no data Available
When is Poniard’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Poniard’s earnings last quarter?
Currently, no data Available
Is Poniard overvalued?
According to Wall Street analysts Poniard’s price is currently Overvalued.
Does Poniard pay dividends?
Poniard does not currently pay dividends.
What is Poniard’s EPS estimate?
Poniard’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poniard have?
Currently, no data Available
What happened to Poniard’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Poniard?
Currently, no hedge funds are holding shares in PARD
Company Description
Poniard
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---